BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21 Suppl 1:5-33. [PMID: 24713004 DOI: 10.1111/jvh.12247] [Cited by in Crossref: 175] [Cited by in F6Publishing: 157] [Article Influence: 21.9] [Reference Citation Analysis]
Number Citing Articles
1 Altınbas S, Holmes JA, Altınbas A. Hepatitis C Virus Infection in Pregnancy: An Update. Gastroenterol Nurs 2020;43:12-21. [PMID: 31990870 DOI: 10.1097/SGA.0000000000000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
2 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
3 Bonacini M, Kim Y, Pitney C, McKoin L, Tran M, Landis C. Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study. J Med Internet Res 2020;22:e15532. [PMID: 32352385 DOI: 10.2196/15532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
5 Jülicher P, Galli C. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting. J Med Econ 2018;21:1-10. [PMID: 28881157 DOI: 10.1080/13696998.2017.1369983] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
6 Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-47. [PMID: 30904068 DOI: 10.1016/j.kint.2018.11.038] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
7 Boix R, Cano R, Gallego P, Vallejo F, Fernández-Cuenca R, Noguer I, Larrauri A. Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study. BMC Health Serv Res 2017;17:461. [PMID: 28679375 DOI: 10.1186/s12913-017-2410-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
9 Miotto N, Mendes LC, Zanaga LP, Lazarini MSK, Goncales ESL, Pedro MN, Goncales FL Jr, Stucchi RSB, Vigani AG. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13:e0199941. [PMID: 29990371 DOI: 10.1371/journal.pone.0199941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
10 Barros MMO, Ronchini KROM, Soares RLS. HEPATITIS B AND C IN PREGNANT WOMEN ATTENDED BY A PRENATAL PROGRAM IN AN UNIVERSITARY HOSPITAL IN RIO DE JANEIRO, BRAZIL: RETROSPECTIVE STUDY OF SEROPREVALENCE SCREENING. Arq Gastroenterol 2018;55:267-73. [PMID: 30540090 DOI: 10.1590/S0004-2803.201800000-68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky J, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology & Hepatology 2018;3:125-33. [DOI: 10.1016/s2468-1253(17)30284-4] [Cited by in Crossref: 89] [Cited by in F6Publishing: 35] [Article Influence: 22.3] [Reference Citation Analysis]
12 Innes H, Goldberg D, Dillon J, Hutchinson SJ. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut 2015;64:1800-9. [PMID: 25378522 DOI: 10.1136/gutjnl-2014-308166] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
13 Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
14 Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34-59. [PMID: 24713005 DOI: 10.1111/jvh.12248] [Cited by in Crossref: 251] [Cited by in F6Publishing: 240] [Article Influence: 31.4] [Reference Citation Analysis]
15 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
17 Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”? World J Hepatol 2015; 7(15): 1936-1952 [PMID: 26244068 DOI: 10.4254/wjh.v7.i15.1936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
18 Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res 2018;248:53-62. [PMID: 29477639 DOI: 10.1016/j.virusres.2018.02.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 20.5] [Reference Citation Analysis]
19 Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609-e616. [PMID: 27470177 DOI: 10.1016/s2214-109x(16)30143-7] [Cited by in Crossref: 656] [Cited by in F6Publishing: 319] [Article Influence: 109.3] [Reference Citation Analysis]
20 Alonso López S, Agudo Fernández S, García Del Val A, Martínez Abad M, López Hermosa Seseña P, Izquierdo MJ, Núñez I, Berbel León S, Visedo Campillo L, Guisado Pérez C, Sánchez Lozano S, Mariño Pfeiffer I, García Bermúdez L, Sánchez Jiménez FJ, López Vega E, Zambrano Álvarez J, Castro Pastor ML, Montes Ramírez G, Murillo C, Villafranca Ortega N, Ayuso Hernández I, Espejo M, Lasala López P, Rodríguez Caravaca G, Carrascosa Aguilar B, Gutiérrez García ML, Fernández Rodríguez C. Hepatitis C seroprevalence in an at-risk population in the southwest Madrid region of Spain. Gastroenterol Hepatol 2016;39:656-62. [PMID: 27417563 DOI: 10.1016/j.gastrohep.2016.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. [PMID: 28683982 DOI: 10.1016/j.drugpo.2017.05.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
22 Saludes V, Antuori A, Reinhardt B, Viciana I, Clavijo E, Schreiber L, Tenenbaum M, Rodriguez-Frias F, Quer J, Matas L, Martró E. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay. Sci Rep 2019;9:3678. [PMID: 30842623 DOI: 10.1038/s41598-019-40099-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017;77:131-44. [PMID: 28074358 DOI: 10.1007/s40265-016-0685-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
24 Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:36-44. [PMID: 28404110 DOI: 10.1016/S2468-1253(16)30002-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
25 Juanbeltz R, Pérez-García A, Aguinaga A, Martínez-Baz I, Casado I, Burgui C, Goñi-Esarte S, Repáraz J, Zozaya JM, San Miguel R, Ezpeleta C, Castilla J; EIPT-VHC Study Group. Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One 2018;13:e0208554. [PMID: 30513107 DOI: 10.1371/journal.pone.0208554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
26 Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, Bahnasy K, Hassan H, Ghoraba D. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2015;42:307-18. [PMID: 26018116 DOI: 10.1111/apt.13261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
27 Razavi H, Bruggmann P, Wedemeyer H, Dore G. Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat 2014;21:e169-70. [DOI: 10.1111/jvh.12339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79. [PMID: 29433454 DOI: 10.1186/s12879-018-2988-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
29 Pronier C, Fontaine H, Dorival C, Carrat F, Pol S, Thibault V; AFEF/ANRS Hepather study group. Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. J Viral Hepat 2019;26:1276-83. [PMID: 31273896 DOI: 10.1111/jvh.13171] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Soipe AI, Razavi H, Razavi-Shearer D, Galárraga O, Taylor LE, Marshall BDL. Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. Epidemiol Infect 2016;144:3376-86. [PMID: 27492142 DOI: 10.1017/S0950268816001722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Sacks-Davis R, van Santen DK, Doyle JS. Commentary on Barré et al. (2020): Identifying remaining barriers to hepatitis C treatment in the DAA era. Addiction 2020;115:583-4. [PMID: 31885116 DOI: 10.1111/add.14887] [Reference Citation Analysis]
32 Rasmussen LD, May MT, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV 2015;2:e288-98. [PMID: 26423253 DOI: 10.1016/S2352-3018(15)00077-6] [Cited by in Crossref: 118] [Cited by in F6Publishing: 55] [Article Influence: 16.9] [Reference Citation Analysis]
33 Chamorro-de-Vega E, Rodríguez-González CG, Giménez-Manzorro Á, Herranz A, Sanjurjo M. Hepatitis C virus infection and the role of a pharmaceutical care program. Am J Health Syst Pharm 2020;77:479-86. [PMID: 31811290 DOI: 10.1093/ajhp/zxz266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Elrazek A, Amer M, El-hawary B, Salah A, Bhagavathula AS, Alboraie M, Saab S. Prediction of HCV vertical transmission: what factors should be optimized using data mining computational analysis. Liver Int 2017;37:529-33. [DOI: 10.1111/liv.13146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
35 Silvestri C, Bartolacci S, Pepe P, Monnini M, Voller F, Cipriani F, Stasi C. Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data. World J Gastroenterol 2016; 22(44): 9829-9835 [PMID: 27956807 DOI: 10.3748/wjg.v22.i44.9829] [Reference Citation Analysis]
36 Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Review of Molecular Diagnostics 2017;17:1109-15. [DOI: 10.1080/14737159.2017.1400385] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
37 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2021:S0210-5705(21)00251-X. [PMID: 34543719 DOI: 10.1016/j.gastrohep.2021.09.003] [Reference Citation Analysis]
38 Gómez-Escolar Viejo L, García Herola A, Sáez Lloret I, Sánchez Ruano F, Clemente Paulino I, Quílez Ivorra C, Almenta Saavedra I, Martínez Pérez D, Valverde de la Osa J. Screening of hepatitis C virus infection in adult general population in Spain. Eur J Gastroenterol Hepatol 2018;30:1077-81. [PMID: 29939868 DOI: 10.1097/MEG.0000000000001190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
39 Bauer-Staeb C, Jörgensen L, Lewis G, Dalman C, Osborn DPJ, Hayes JF. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry 2017;4:685-93. [PMID: 28687481 DOI: 10.1016/S2215-0366(17)30253-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
40 Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe: HCV Genotype Distribution in Europe Review. J Med Virol 2016;88:2157-69. [DOI: 10.1002/jmv.24573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
41 Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc. 2017;20:22146. [PMID: 28782335 DOI: 10.7448/ias.20.1.22146] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
42 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
43 Alavi M, Law MG, Grebely J, Amin J, Hajarizadeh B, George J, Dore GJ. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. Journal of Hepatology 2016;65:879-87. [DOI: 10.1016/j.jhep.2016.06.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
44 Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One 2015;10:e0126920. [PMID: 25961575 DOI: 10.1371/journal.pone.0126920] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
45 Kondili LA, Andreoni M, Alberti A, Lobello S, Babudieri S, Roscini AS, Merolla R, Marrocco W, Craxì A. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. Epidemics 2021;34:100442. [PMID: 33607538 DOI: 10.1016/j.epidem.2021.100442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Wang Y, Tan XD, Zhou C, Zhou W, Peng JS, Ren YS, Ni ZL, Liu B, Yang F, Gao XD. Exploratory social network analysis and gene sequencing in people who inject drugs infected with hepatitis C virus. Epidemiol Infect 2016;144:3080-90. [PMID: 27405277 DOI: 10.1017/S0950268816001333] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Carvalho TL, Lima RE, Góes GHB, Pereira LA, Fernandes MSS, Moura PMMF, Vasconcelos LRS, Correia CC. Cognitive Dysfunction and Single Nucleotide Polymorphisms in Hepatitis C Virus-Infected Persons: A Systematic Review. Viral Immunol 2017;30:703-7. [PMID: 29016246 DOI: 10.1089/vim.2017.0084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
48 Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol 2016; 22(6): 1953-1965 [PMID: 26877603 DOI: 10.3748/wjg.v22.i6.1953] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
49 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Gomide GPM, Melo CB, Santos VDS, Salge VD, Camargo FC, Pereira GA, Cabral SCO, Molina RJ, Oliveira CDCHB. Epidemiological survey of hepatitis C in a region considered to have high prevalence: the state of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2019;52:e20190202. [PMID: 31596352 DOI: 10.1590/0037-8682-0202-2019] [Reference Citation Analysis]
51 Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat 2015;22 Suppl 1:1-5. [PMID: 25560838 DOI: 10.1111/jvh.12371] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
52 Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvåg BK, Sundin CG, Brytting M, Esbjörnsson J, Mild M. Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns. Infect Ecol Epidemiol 2016;6:30670. [PMID: 26854010 DOI: 10.3402/iee.v6.30670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42:696-706. [PMID: 26202593 DOI: 10.1111/apt.13316] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
54 Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014;29 Suppl 1:1-9. [PMID: 25055928 DOI: 10.1111/jgh.12677] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
55 Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 2018;21 Suppl 2:e25058. [PMID: 29633561 DOI: 10.1002/jia2.25058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
56 Ascione A, Fontanella L, Imparato M, Rinaldi L, De Luca M. Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years. Liver Int. 2017;37:1193-1201. [PMID: 28111883 DOI: 10.1111/liv.13371] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
57 Bertisch B, Giudici F, Negro F, Moradpour D, Müllhaupt B, Moriggia A, Estill J, Keiser O; Swiss Hepatitis C Cohort Study. Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. PLoS One 2016;11:e0155464. [PMID: 27227332 DOI: 10.1371/journal.pone.0155464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
58 Bielen R, Kremer C, Koc ÖM, Busschots D, Hendrickx DM, Vanelderen P, Hens N, Nevens F, Robaeys G. Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium? Liver Int 2019;39:667-75. [PMID: 30525269 DOI: 10.1111/liv.14016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
59 Polilli E, Tontodonati M, Flacco ME, Ursini T, Striani P, Di Giammartino D, Paoloni M, Vallarola L, Pressanti GL, Fragassi G, Accorsi P, Manzoli L, Parruti G. High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening. Infection 2016;44:85-91. [PMID: 26363567 DOI: 10.1007/s15010-015-0841-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
60 Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. J Int AIDS Soc 2018;21 Suppl 2:e25051. [PMID: 29633559 DOI: 10.1002/jia2.25051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
61 Muñoz-espinosa LE, Trujillo-trujillo ME, Martínez-macías RF, Panduro A, Rivas-estilla AM, Fierro NA, Silvera-linares AL, Torres-valadez R, Cordero-pérez P, González-aldaco K, Chen-lópez CY, José-abrego A, Zuñiga-noriega JR, Gutiérrez-ruiz MC, Roman S. Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology 2015;14:642-51. [DOI: 10.1016/s1665-2681(19)30758-6] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
62 Valença IN, Santos RBD, Peronni KC, Sauvage V, Vandenbogaert M, Caro V, Silva Junior WAD, Covas DT, Silva-Pinto AC, Laperche S, Kashima S, Slavov SN. Deep sequencing applied to the analysis of viromes in patients with beta-thalassemia. Rev Inst Med Trop Sao Paulo 2021;63:e40. [PMID: 34037156 DOI: 10.1590/S1678-9946202163040] [Reference Citation Analysis]
63 Chen P, Zheng Y, Cai Y, Zou P, Li N, Peng C, Gao H, Liu J, Chen Y, Tong Z, Li L. Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study. Can J Gastroenterol Hepatol 2020;2020:8219536. [PMID: 32377514 DOI: 10.1155/2020/8219536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV. The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clin Infect Dis. 2019;69:2218-2227. [PMID: 31352481 DOI: 10.1093/cid/ciz714] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
65 Cooper C. Rapid HCV RNA testing: removing the final obstacle to elimination. Lancet Gastroenterol Hepatol 2017;2:468-9. [PMID: 28442272 DOI: 10.1016/S2468-1253(17)30086-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Pinto FP, Ferreira OC Jr, Olmedo DB, Precioso PM, Barquette FR, Castilho MC, Silva SG, Pôrto LC. Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study. Ann Hepatol 2015;14:815-25. [PMID: 26436353 DOI: 10.5604/16652681.1171756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 394] [Cited by in F6Publishing: 334] [Article Influence: 65.7] [Reference Citation Analysis]
68 Grebely J, Lamoury FMJ, Hajarizadeh B, Mowat Y, Marshall AD, Bajis S, Marks P, Amin J, Smith J, Edwards M, Gorton C, Ezard N, Persing D, Kleman M, Cunningham P, Catlett B, Dore GJ, Applegate TL. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. The Lancet Gastroenterology & Hepatology 2017;2:514-20. [DOI: 10.1016/s2468-1253(17)30075-4] [Cited by in Crossref: 97] [Cited by in F6Publishing: 26] [Article Influence: 19.4] [Reference Citation Analysis]
69 Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales FL Jr, Stucchi RS, Vigani AG. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res 2016;49:S0100-879X2016000700702. [PMID: 27356107 DOI: 10.1590/1414-431X20165300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
70 Carvalho-Louro DM, Soares EB, Trevizoli JE, Marra TMG, da Cunha ALR, Rodrigues MP, Carvalho-Furtado ACL, Dos Santos BTA, de Assis da Rocha Neves F. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis 2020;20:114. [PMID: 32041537 DOI: 10.1186/s12879-020-4809-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
71 Gahrton C, Westman G, Lindahl K, Öhrn F, Dalgard O, Lidman C, Nilsson LH, Said K, Duberg AS, Aleman S. Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infect Dis 2019;19:955. [PMID: 31706284 DOI: 10.1186/s12879-019-4581-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
72 Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida EC, Vivaldini S, Fernandes N, Razavi H, Schmelzer J, Ferraz ML, Ferreira PRA, Pessoa MG, Martinelli A, Souto FJD, Walsh N, Mendes-Correa MC. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Braz J Infect Dis 2019;23:182-90. [PMID: 31145876 DOI: 10.1016/j.bjid.2019.04.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
73 van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky J, Cloherty GA, Duarte-rojo A, Sarrazin C, Wedemeyer H, Feld JJ. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. The Lancet Gastroenterology & Hepatology 2018;3:856-64. [DOI: 10.1016/s2468-1253(18)30271-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
74 Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O. HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology 2016;65:S33-45. [DOI: 10.1016/j.jhep.2016.07.012] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 16.8] [Reference Citation Analysis]
75 Chaabna K, Cheema S, Abraham A, Alrouh H, Lowenfels AB, Maisonneuve P, Mamtani R. Systematic overview of hepatitis C infection in the Middle East and North Africa. World J Gastroenterol 2018; 24(27): 3038-3054 [PMID: 30038471 DOI: 10.3748/wjg.v24.i27.3038] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
76 Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res 2017;37:348-53. [PMID: 28777714 DOI: 10.1089/jir.2016.0131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Borges M, Gouveia M, Fiorentino F, Jesus G, Cary M, Guerreiro JP, Costa S, Carneiro AV. Costs and consequences of the Portuguese needle-exchange program in community pharmacies. Can Pharm J (Ott) 2020;153:170-8. [PMID: 32528601 DOI: 10.1177/1715163520915744] [Reference Citation Analysis]
78 Aguinaga A, Díaz-González J, Pérez-García A, Barrado L, Martínez-Baz I, Casado I, Juanbeltz R, Ezpeleta C, Castilla J. The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014-2016. Enferm Infecc Microbiol Clin (Engl Ed) 2018;36:325-31. [PMID: 28110858 DOI: 10.1016/j.eimc.2016.12.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
79 Millbourn C, Lybeck C, Psaros Einberg A, Nordin M, Lindh G, Hökeberg I, Fredlund H, Fischler B, Fadl H, Duberg AS, Lindahl K. Anti-HCV prevalence and risk factor-based screening for hepatitis C in pregnant women and their partners in Sweden. Infect Dis (Lond) 2020;52:776-85. [PMID: 32654571 DOI: 10.1080/23744235.2020.1784456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60-89. [PMID: 24713006 DOI: 10.1111/jvh.12249] [Cited by in Crossref: 139] [Cited by in F6Publishing: 132] [Article Influence: 17.4] [Reference Citation Analysis]
81 Marcellusi A, Viti R, Capone A, Mennini FS. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness. PharmacoEcon Ital Res Artic 2014;16. [DOI: 10.1007/s40276-014-0023-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Oliva-Moreno J, Peña-Longobardo LM, Alonso S, Fernández-Bolaños A, Gutiérrez ML, Hidalgo-Vega Á, de la Fuente E, Fernández-Rodríguez CM. Labour productivity losses caused by premature death associated with hepatitis C in Spain. Eur J Gastroenterol Hepatol 2015;27:631-7. [PMID: 25853930 DOI: 10.1097/MEG.0000000000000336] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
83 Lazarus JV, Bromberg DJ. Commentary on Trias-Llimós et al. (2017): Birth cohort research-an essential tool to guide public health interventions. Addiction 2017;112:259-60. [PMID: 28078704 DOI: 10.1111/add.13679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
84 Walewska-Zielecka B, Religioni U, Juszczyk G, Wawrzyniak ZM, Czerw A, Soszyński P, Fronczak A. Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014. Euro Surveill 2017;22:30441. [PMID: 28106526 DOI: 10.2807/1560-7917.ES.2017.22.2.30441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
85 Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holten J, Xie F, Druyts E. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. [PMID: 31922124 DOI: 10.1016/j.eclinm.2019.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
86 Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87-S99. [PMID: 25920094 DOI: 10.1016/j.jhep.2015.02.006] [Cited by in Crossref: 217] [Cited by in F6Publishing: 205] [Article Influence: 36.2] [Reference Citation Analysis]
88 Ascencio-Montiel IJ. Hepatitis C in the three main health institutions in Mexico: a 13-year mortality and hospitalization analysis. Rev Inst Med Trop Sao Paulo 2020;62:e11. [PMID: 32049262 DOI: 10.1590/S1678-9946202062011] [Reference Citation Analysis]
89 Schröeder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver Int 2019;39:1818-36. [PMID: 31433902 DOI: 10.1111/liv.14222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
90 McLeod A, Cullen BL, Hutchinson SJ, Roy KM, Dillon JF, Stewart EA, Goldberg DJ. Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. J Viral Hepat 2017;24:944-54. [PMID: 28502088 DOI: 10.1111/jvh.12724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
91 Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am. 2015;44:807-824. [PMID: 26600221 DOI: 10.1016/j.gtc.2015.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
92 Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat 2019;26:1388-403. [PMID: 31392812 DOI: 10.1111/jvh.13187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
93 Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
94 Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C, Lutz T, Pfeiffer-Vornkahl H, Niederau C, Cornberg M, Sarrazin C, Mauss S. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int 2017;37:205-11. [PMID: 27428297 DOI: 10.1111/liv.13206] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
95 Pedersen J, Lundbo LF, Krarup H, Bukh J, Weis N. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection. J Med Virol 2016;88:1791-803. [PMID: 27027386 DOI: 10.1002/jmv.24537] [Reference Citation Analysis]
96 Jiménez-Macías FM, Cabanillas-Casafranca M, Maraver-Zamora M, Romero-Herrera G, García-García F, Correia-Varela-Almeida A, Cabello-Fernández A, Ramos-Lora M. Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C. Med Clin (Barc) 2017;149:375-82. [PMID: 28416232 DOI: 10.1016/j.medcli.2017.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
97 Dröse S, Øvrehus ALH, Holm DK, Madsen LW, Mössner BK, Søholm J, Hansen JF, Røge BT, Christensen PB. A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project. BMC Infect Dis 2022;22:202. [PMID: 35232372 DOI: 10.1186/s12879-022-07196-7] [Reference Citation Analysis]
98 Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70. [DOI: 10.1007/s12072-016-9748-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
99 Marinho RT, Costa A, Pires T, Raposo H, Vasconcelos C, Polónia C, Borges J, Soares M, Vilar G, Nogueira AM; LIGUE-C Investigators. A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. BMC Infect Dis 2016;16:565. [PMID: 27733137 DOI: 10.1186/s12879-016-1883-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
100 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
101 Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T. Increased hope following successful treatment for hepatitis C infection. J Adv Nurs 2018;74:724-33. [PMID: 29082540 DOI: 10.1111/jan.13487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
102 McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? J Hepatol 2015;62:262-8. [PMID: 25195556 DOI: 10.1016/j.jhep.2014.08.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
103 Johnson SJ, Parisé H, Virabhak S, Filipovic I, Samp JC, Misurski D. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ 2016;19:983-94. [PMID: 27172133 DOI: 10.1080/13696998.2016.1189920] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
104 Innes H, Hutchinson SJ, Obel N, Christensen PB, Aspinall EJ, Goldberg D, Krarup H, McDonald SA, McLeod A, Weir A, Omland LH. Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator. Hepatology 2016;63:1506-16. [PMID: 26773546 DOI: 10.1002/hep.28458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
105 Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015. Journal of Hepatology 2017;67:15-22. [DOI: 10.1016/j.jhep.2017.01.024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
106 Miller FD, Elzalabany MS, Hassani S, Cuadros DF. Epidemiology of hepatitis C virus exposure in Egypt: Opportunities for prevention and evaluation. World J Hepatol 2015; 7(28): 2849-2858 [PMID: 26668697 DOI: 10.4254/wjh.v7.i28.2849] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
107 Saab S, Viramontes MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG, Saab EG, Saab CE, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M. Hepatitis C Virus Prevalence in Egyptian Americans in Southern California. J Clin Gastroenterol 2018;52:55-9. [PMID: 28617761 DOI: 10.1097/MCG.0000000000000858] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Ingiliz P, Rockstroh JK. Hepatitis C virus reinfection-more to come? Lancet Gastroenterol Hepatol 2017;2:150-1. [PMID: 28404124 DOI: 10.1016/S2468-1253(16)30223-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Benova L, Awad SF, Miller FD, Abu-Raddad LJ. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt. Hepatology 2015;61:834-42. [PMID: 25366418 DOI: 10.1002/hep.27596] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
110 Krüger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Müller T, Klinker H, Pathil A, Heyne R, Stahmeyer JT; Collaborators DHC-R. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2019;31:230-40. [PMID: 30325794 DOI: 10.1097/MEG.0000000000001283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
111 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
112 Büsch K, Waldenström J, Lagging M, Aleman S, Weiland O, Kövamees J, Duberg A, Söderholm J. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology 2017;52:61-8. [DOI: 10.1080/00365521.2016.1228119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
113 Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46 Suppl 5:S158-S164. [PMID: 25453870 DOI: 10.1016/j.dld.2014.09.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
114 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. PLoS One 2016;11:e0153895. [PMID: 27100663 DOI: 10.1371/journal.pone.0153895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
116 Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? PLoS One 2018;13:e0209374. [PMID: 30596701 DOI: 10.1371/journal.pone.0209374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
117 Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-S57. [PMID: 25086286 DOI: 10.1016/j.jhep.2014.07.027] [Cited by in Crossref: 1189] [Cited by in F6Publishing: 1085] [Article Influence: 148.6] [Reference Citation Analysis]
118 Fattahi MR, Safarpour A, Sepehrimanesh M, Hosseini Asl SM, Mohamaddoust F. The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran. Hepat Mon 2015;15:e24734. [PMID: 25788957 DOI: 10.5812/hepatmon.24734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
119 Alboraie M, Yousef NF, El Kassas M. Egyptian liver library: Rebuilding the pyramid of liver disease evidence in Egypt. Arab J Gastroenterol 2017;18:189. [PMID: 28958639 DOI: 10.1016/j.ajg.2017.09.007] [Reference Citation Analysis]
120 Bajis S, Maher L, Treloar C, Hajarizadeh B, Lamoury FMJ, Mowat Y, Schulz M, Marshall AD, Cunningham EB, Cock V, Ezard N, Gorton C, Hayllar J, Smith J, Whelan M, Martinello M, Applegate TL, Dore GJ, Grebely J; LiveRLife Study Group. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. Int J Drug Policy 2018;61:23-30. [PMID: 30388566 DOI: 10.1016/j.drugpo.2018.08.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
121 Thönnes S, Friedel H, Fröhlich H. The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data. Eur J Gastroenterol Hepatol 2017;29:503-8. [PMID: 28092642 DOI: 10.1097/MEG.0000000000000819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Helal TEA, Radwan NA, Mahmoud HA, Zaki AM, Ahmed NS, Wahib AA, Aref AM. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4. Afr Health Sci 2019;19:1411-21. [PMID: 31148968 DOI: 10.4314/ahs.v19i1.14] [Reference Citation Analysis]
123 Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One 2017;12:e0169401. [PMID: 28046099 DOI: 10.1371/journal.pone.0169401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
124 Trinks J, Caputo M, Hulaniuk ML, Corach D, Flichman D. Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. Pharmgenomics Pers Med 2017;10:79-91. [PMID: 28405170 DOI: 10.2147/PGPM.S125452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
125 Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Cohen Eliav M, Skorochod Y, Breuer GS, Tur-Kaspa R, Weil Wiener Y, Stern A, Cotler SJ, Dahari H, Lurie Y. Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. PLoS One 2019;14:e0210173. [PMID: 30645600 DOI: 10.1371/journal.pone.0210173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis 2019;19:1019. [PMID: 31791253 DOI: 10.1186/s12879-019-4524-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
127 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
128 Hickman M, Martin N, Vickerman P, Hutchinson S. Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. J Viral Hepat 2014;21:e167-8. [DOI: 10.1111/jvh.12340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
129 Mattlinger C, Thumfart JO, Heinen W, Michels H, Berres M, Vogt M, Jansky M. [Hepatitis C virus seroprevalence and dependency on country of origin of refugees in Rhineland-Palatinate, Germany in 2015]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61:1472-80. [PMID: 30225596 DOI: 10.1007/s00103-018-2816-x] [Reference Citation Analysis]
130 Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization: Epidemiology of Hepatitis C in a large Israeli HMO. J Med Virol 2016;88:1044-50. [DOI: 10.1002/jmv.24426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
131 Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol 2015;50:233-44. [PMID: 25515032 DOI: 10.3109/00365521.2014.990505] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
132 Younossi Z, Brown A, Buti M, Fagiuoli S, Mauss S, Rosenberg W, Serfaty L, Srivastava A, Smith N, Stepanova M, Beckerman R. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 2016;23:217-26. [PMID: 26482680 DOI: 10.1111/jvh.12483] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
133 Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden - volume 3 (editorial). J Viral Hepat. 2015;22 Suppl 4:1-3. [PMID: 26513444 DOI: 10.1111/jvh.12473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
134 Crespo J, Cuadrado A, Perelló C, Cabezas J, Llerena S, Llorca J, Cedillo S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Lazarus JV, Calleja JL. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. J Viral Hepat 2020;27:360-70. [PMID: 31755634 DOI: 10.1111/jvh.13238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
135 Sbarigia U, Wirth D, Van Nuys K, Huber C, Brookmeyer R, Stahmeyer J, Krauth C. Economic study of the value of expanding HCV treatment capacity in Germany. BMJ Open Gastroenterol 2017;4:e000130. [PMID: 28461903 DOI: 10.1136/bmjgast-2016-000130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
136 Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C. The Elimination of Hepatitis C as a Public Health Threat. Cold Spring Harb Perspect Med 2020;10:a036939. [PMID: 31712223 DOI: 10.1101/cshperspect.a036939] [Reference Citation Analysis]
137 Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis 2018;18:42. [PMID: 29338702 DOI: 10.1186/s12879-017-2908-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
138 Saludes V, Folch C, Morales-Carmona A, Ferrer L, Fernàndez-López L, Muñoz R, Jiménez M, Loureiro E, Fernández-Dávila P, Bascuñana E, Casabona J, Martró E. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: Analysis of key populations in Barcelona, Spain. J Viral Hepat 2018;25:236-44. [PMID: 29053912 DOI: 10.1111/jvh.12809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
139 Zeuzem S. Treatment Options in Hepatitis C. Dtsch Arztebl Int 2017;114:11-21. [PMID: 28143635 DOI: 10.3238/arztebl.2017.0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
140 Miotto N, Mendes LC, Zanaga LP, Goncales ESL, Lazarini MSK, Pedro MN, Gonçales FL Jr, Stucchi RSB, Vigani AG. Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. Eur J Gastroenterol Hepatol 2017;29:1149-54. [PMID: 28800033 DOI: 10.1097/MEG.0000000000000944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
141 Ponnuvel S, Fletcher GJ, Anantharam R, Varughese S, David VG, Abraham P. Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients. PLoS One 2021;16:e0250263. [PMID: 33886631 DOI: 10.1371/journal.pone.0250263] [Reference Citation Analysis]
142 Morales-Arraez D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, Jiménez A, Garcia Dopico JA, Quintero E, Hernández-Guerra M. Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. Eur J Gastroenterol Hepatol 2020;32:528-34. [PMID: 31490420 DOI: 10.1097/MEG.0000000000001534] [Reference Citation Analysis]
143 Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS One 2015;10:e0125214. [PMID: 26107467 DOI: 10.1371/journal.pone.0125214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
144 Day E, Broder T, Bruneau J, Cruse S, Dickie M, Fish S, Grillon C, Luhmann N, Mason K, Mclean E, Trooskin S, Treloar C, Grebely J. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. International Journal of Drug Policy 2019;66:87-93. [DOI: 10.1016/j.drugpo.2019.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
145 Dore GJ, Hatzakis A, Negro F, Waked I. Estimating HCV disease burden-volume 4 (editorial). J Viral Hepat 2017;24 Suppl 2:4-7. [PMID: 29105284 DOI: 10.1111/jvh.12763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
146 Zimmermann R, Kollan C, Ingiliz P, Mauss S, Schmidt D, Bremer V. Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”. Journal of Hepatology 2017;67:420-2. [DOI: 10.1016/j.jhep.2017.03.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
147 Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 2017;24:840-9. [DOI: 10.1111/jvh.12708] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
149 Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M, Balslev U, Belard E, Øvrehus A, Skalshøi Kjær M, Krarup H, Thorup Røge B, Hallager S, Madsen LG, Lund Laursen A, Lagging M, Weis N. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLoS One 2017;12:e0179764. [PMID: 28704381 DOI: 10.1371/journal.pone.0179764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
150 Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol 2017;14:641-51. [DOI: 10.1038/nrgastro.2017.106] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 18.4] [Reference Citation Analysis]
151 von Aesch Z, Craig-Neil A, Shah H, Antoniou T, Meaney C, Pinto AD. Family medicine-directed hepatitis C care and barriers to treatment: a mixed-methods study. CMAJ Open 2021;9:E201-7. [PMID: 33688028 DOI: 10.9778/cmajo.20190194] [Reference Citation Analysis]
152 Cheng ML, Abdel-hakeem MS, Cousineau SE, Grebely J, Marshall AD, Saeed S, Sagan SM, Shoukry NH, Feld JJ, Macparland SA. The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of HCV: How to Get There”. CanLivJ 2018;1:139-52. [DOI: 10.3138/canlivj.2018-0018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. International Journal of Drug Policy 2017;47:34-46. [DOI: 10.1016/j.drugpo.2017.07.002] [Cited by in Crossref: 108] [Cited by in F6Publishing: 105] [Article Influence: 21.6] [Reference Citation Analysis]
154 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
155 Pozzetto B, Memmi M, Garraud O, Roblin X, Berthelot P. Health care-associated hepatitis C virus infection. World J Gastroenterol 2014; 20(46): 17265-17278 [PMID: 25516637 DOI: 10.3748/wjg.v20.i46.17265] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
156 Mössner BK, Staugaard B, Jensen J, Lillevang ST, Christensen PB, Holm DK. Dried blood spots, valid screening for viral hepatitis and human immunodeficiency virus in real-life. World J Gastroenterol 2016; 22(33): 7604-7612 [PMID: 27672281 DOI: 10.3748/wjg.v22.i33.7604] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
157 Lamoury FMJ, Bajis S, Hajarizadeh B, Marshall AD, Martinello M, Ivanova E, Catlett B, Mowat Y, Marks P, Amin J, Smith J, Ezard N, Cock V, Hayllar J, Persing DH, Kleman M, Cunningham P, Dore GJ, Applegate TL, Grebely J; LiveRLife Study Group. Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. The Journal of Infectious Diseases 2018;217:1889-96. [DOI: 10.1093/infdis/jiy114] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
158 Ndjoyi-Mbiguino A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, Akombi FL, Nzengui Nzengui F, M'boyis Kamdem H, François-Souquière S. Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon. PLoS One 2018;13:e0190529. [PMID: 29385148 DOI: 10.1371/journal.pone.0190529] [Reference Citation Analysis]
159 Vaziri A, Gimson A, Agarwal K, Aldersley M, Bathgate A, MacDonald D, McPherson S, Mutimer D, Gelson W. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. J Viral Hepat. 2019;26:231-235. [PMID: 30339294 DOI: 10.1111/jvh.13022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
160 Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wien Klin Wochenschr 2017;129:517-26. [PMID: 28130599 DOI: 10.1007/s00508-016-1162-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
161 Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One 2016;11:e0159976. [PMID: 27467772 DOI: 10.1371/journal.pone.0159976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]